This practice is particularly important for individuals using lower doses (0.25 mg or 0.5 mg weekly), as these pens may contain sufficient medication for multiple weeks of treatment
Among the available options are: These medications are prescribed as part of a structured, doctor-monitored programme that includes medical assessment, dose adjustments, and ongoing follow-up to ensure safe and sustainable results
Newer agents, including GLP-1/GIP/glucagon receptor agonists, may offer additional metabolic advantages and seem to preserve a proportionally greater fraction of lean mass compared with older agents, though their effects on cardiorespiratory fitness differ from those of structured exercise
Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, et al
Upon examining the prior medication research on MASLD, we found that despite notable progress in the treatment of MASLD in recent decades, none of the medications have official approval [41]